ArticleCancer research2020
Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Aberrant Energy Metabolism in Tumors and Potential Therapeutic Targets.Genes, chromosomes & cancer · 2024Pooled it
- FMolecular biology reports · 2023Pooled it
- A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer.Breast cancer research and treatment · 2021Trial
- Targeting tumor dormancy: the next frontier in gastrointestinal stromal tumor therapy.Neoplasia (New York, N.Y.) · 2026Review
- Review
- Revolutionizing Breast Cancer Treatment: Harnessing Ehrlich Ascites Carcinoma Model, Cancer Metabolism, and Nanotechnology-Enhanced Chemotherapy for Improved Patient Outcomes.Cell biochemistry and biophysics · 2026Review
- Role of RGS12 in placental mitochondrial dysfunction and adverse pregnancy outcomes.Cellular and molecular life sciences : CMLS · 2026Article
- Extracellular lactate improves neurogenesis by modulating H3K9 lactylation and SnoN expression under hypoxic conditions.Stem cell research & therapy · 2025Article
- Personalized cancer treatment strategies incorporating irreversible and reversible drug resistance mechanisms.NPJ systems biology and applications · 2025Article
- Metabolic hallmarks of trastuzumab resistance.Expert opinion on therapeutic targets · 2025Review
- Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment.Molecular cancer · 2025Review
- Imaging phenotype reveals that disulfirams induce protein insolubility in the mitochondrial matrix.Scientific reports · 2024Article
- Adenosine diphosphate released from stressed cells triggers mitochondrial transfer to achieve tissue homeostasis.PLoS biology · 2024Article
- Proteomic Characterization of a 3D HER2+ Breast Cancer Model Reveals the Role of Mitochondrial Complex I in Acquired Resistance to Trastuzumab.International journal of molecular sciences · 2024Article
- Cuproptosis-related genes predict prognosis and trastuzumab therapeutic response in HER2-positive breast cancer.Scientific reports · 2024Article
- Article
- Mitochondrial inhibitors: a new horizon in breast cancer therapy.Frontiers in pharmacology · 2024Review
- Chromatin Organization and Transcriptional Programming of Breast Cancer Cell Identity.Endocrinology · 2023Review
- Potential targets and applications of nanodrug targeting myeloid cells in osteosarcoma for the enhancement of immunotherapy.Frontiers in pharmacology · 2023Review
- COX2-ATP Synthase Regulates Spine Follicle Size in Hedgehogs.International journal of biological sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 4 countries.
Molly Gale *Department of Pathology, Yale School of Medicine, New Haven, Connecticut.
Yao LiDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut.
Jian CaoDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut.
Zongzhi Z Liu *Department of Pathology, Yale School of Medicine, New Haven, Connecticut.
Marissa A HolmbeckDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut.
Meiling ZhangDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut.
Sabine M LangDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut.
Lizhen WuDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut.
Mariana Do CarmoDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut.
Swati GuptaDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut.
Keisuke AoshimaDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0002-2987-0793
Michael P DiGiovannaYale Cancer Center, Yale School of Medicine, New Haven, Connecticut.
David F SternDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0003-4018-5348
David L RimmDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut.
Gerald S ShadelSalk Institute for Biological Studies, La Jolla, California.
Xiang ChenDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China. qin.yan@yale.edu chenxiangck@126.com.
Qin YanDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut. qin.yan@yale.edu chenxiangck@126.com.ORCID 0000-0003-4077-453X
Yale University · USYale Cancer Center · USCentral South University · CNHokkaido University of Science · JPSalk Institute for Biological Studies · US
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MYale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI DAVID L RIMM · 1985 to 2026
$85.0MViral Vector Core (VVC)P30CA014195 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Ye Zheng · 1985 to 2026
$82.8M(PQ5) Mitochondrial Heterogeneity in Melanoma Tumor and Immune ResponsesR01CA216101 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI GERALD SHADEL · 2018 to 2026
$5.0MIDENTIFYING EPIGENETIC CHANGES CRITICAL FOR TRASTUZUMAB RESISTANCER21CA187862 · NCI · YALE UNIVERSITY · PI YAN, QIN · 2015 to 2016
$398kThe role of mitochondrial localized Ago2 and miRNAs in regulating mitochondrial function and agingF32AG052995 · NIA · YALE UNIVERSITY · PI HOLMBECK, MARISSA · 2016 to 2019
$141kNCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA014195NCI NIH HHS P30 CA016359NCI NIH HHS R01 CA216101NCI NIH HHS R21 CA187862NIA NIH HHS F32 AG052995
Abstract
Acquired resistance to HER2-targeted therapies occurs frequently in HER2
Indexed as
AnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisBreast NeoplasmsCell ProliferationDrug Resistance, NeoplasmEnzyme InhibitorsErb-b2 Receptor Tyrosine KinasesFemaleHumansMiceMice, Inbred NODMice, SCIDMitochondrial Proton-Translocating ATPasesOligomycinsTrastuzumabATP5F1B protein, humanEnzyme InhibitorsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesMitochondrial Proton-Translocating ATPasesoligomycin AOligomycinsTrastuzumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.